Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016
October 26 2016 - 8:00AM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies based upon tetracycline chemistry, today
announced that the Company will host an R&D Day on Thursday,
November 17, 2016, from 1:00 p.m. to 3:00 p.m. ET at Lotte Palace
Hotel in New York City.
During the R&D day, Paratek’s management team and opinion
leaders in the field of antibiotics development and infectious
disease will discuss progress of the clinical development program
for omadacycline, including the following:
- Provide a company update
- Discuss the company’s efforts to advance clinical development
for omadacycline’s use in UTI
- Report results from additional registration enabling Phase 1
studies
- Clinical unmet needs in ABSSSI, CABP and UTI and the value of
an IV and Oral treatment option
Speakers will include:
Keith Rodvold, Pharm D University of Illinois at Chicago
Chicago, IL
J. Scott Overcash, MD Grossmont Emergency Medical Group San
Diego, CA
Tom Lodise, Pharm D, PhD Albany College of Pharmacy and Health
Sciences Albany, NY
Alpesh Amin, MD University of California, Irvine, CA
Webcast Information A live webcast of the
R&D Day and replay will be available online from the Events and
Presentations section of Paratek’s website at
www.paratekpharma.com. A replay of the presentation will be posted
on the Paratek website approximately one hour after the live event
and will be available for 30 days following the presentation.
About Paratek Pharmaceuticals,
Inc. Paratek Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies based upon its expertise
in novel tetracycline chemistry. Paratek's lead product candidate,
omadacycline, is the first in a new class of tetracyclines known as
aminomethylcyclines, with broad-spectrum activity against
Gram-positive, Gram-negative and atypical bacteria. In June 2016
Paratek announced positive efficacy data in a Phase 3 registration
study in ABSSSI demonstrating the efficacy and safety of
intravenous (IV) to oral omadacycline compared to linezolid. A
Phase 3 registration study for community acquired bacterial
pneumonia (CABP) comparing IV-to-oral omadacycline to IV-to-oral
moxifloxacin was initiated in November 2015. Enrollment
continues on track to report top line data as early as the third
quarter of 2017. A Phase 3 registration study in ABSSSI
comparing once-daily oral-only dosing of omadacycline to
twice-daily oral-only dosing of linezolid was initiated in August
2016. Top line data are expected as early as the second quarter of
2017. A Phase 1B study in uncomplicated urinary tract infections
(UTI) was initiated in May 2016. Omadacycline has been granted
Qualified Infectious Disease Product designation and Fast Track
status by the U.S. Food and Drug Administration.
Omadacycline is a new once-daily oral and IV, well-tolerated
broad spectrum antibiotic being developed for use as empiric
monotherapy for patients suffering from serious community-acquired
bacterial infections, such as acute bacterial skin and skin
structure infections, community acquired bacterial pneumonia,
urinary tract infections and other community-acquired bacterial
infections, particularly when antibiotic resistance is of concern
to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a
well-tolerated, once-daily, oral, narrow spectrum
tetracycline-derived antibiotic with potent anti-inflammatory
properties for the potential treatment of acne and rosacea in the
community setting. Allergan owns the U.S. rights for the
development and commercialization of sarecycline. Paratek retains
all ex-U.S. rights. Allergan initiated two identical Phase 3
registration studies in December 2014 for sarecycline for the
treatment of moderate to severe acne vulgaris. Top line data are
expected in the first half of 2017.
For more information, visit www.paratekpharma.com.
CONTACTS:
Media:
Michael Lampe
Scient Public Relations
(484) 575-5040
michael@scientpr.com
Investors:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024